The future of the global structural heart device market looks promising with opportunities in the aorta and mitral markets.
- Within the procedure category, repair is expected to witness higher growth over the forecast period due to increasing demand for minimally invasive repair procedures.
- Within the position category, aorta is expected to witness the highest growth over the forecast period due to rising aortic disease prevalence and surgical interventions.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to growing adoption healthcare infrastructure and advanced treatment.
Emerging Trends in Structural Heart Device Market
The market will shift from focusing on the number of procedures to lifetime management between 2025 and 2027. Transcatheter solutions will move to lower-risk patient populations. The use of advanced imaging, as well as the generation of evidence, and hospital economics will shape purchasing decisions. During this period, Lucintel expects that competition will intensify as manufacturers extend their current platforms to cover transcatheter valve repair and replacement and closure of the left atrial appendage.- TAVR Expansion: Between 2015 and 2025, more than 300,000 TAVR procedures will be performed worldwide as the FDA continues to broaden its indications and approve label expansions for TAVR for younger populations. As the population of patients receiving the procedure grows, clinicians will put more pressure on manufacturers to develop next-generation devices that reduce length of stay and improve recovery times.
- Durability and Lifetime Management: Between 2023 and 2025, more data will show the durability of transcatheter valves and further reinforce the performance of transcatheter valves. As durability is further validated, clinicians will put pressure on manufacturers to develop a transcatheter platform for valve-in-valve procedures and to manage the hemodynamics of the patient for an extended period of time.
- Image-guided Precision: With the use of advanced imaging, 3D CT planning will be used in conjunction with echocardiography to better position devices, further reducing uncertainty and complications. This will allow clinicians to extend treatment to more complex cases.
- Expansion of Adjacent Indications: Clinical trials between 2023 and 2025 will aid in the advancement of transcatheter solutions for mitral and tricuspid valve repair and replacement, as well as closure of the left atrial appendage.
- Value-based Hospital Adoption: Hospitals are closely scrutinizing total episode cost as case volumes increase; TAVR stays are often less than one day at high volume sites, as compared to several days for a standard open surgical procedure. It is anticipated that in the next three to five years, procurement will favor platforms that provide clinical outcomes and predictable use of resources.
Recent Developments in the Structural Heart Device Market
The structural heart device market is expanding from specialty markets to other areas of cardiovascular care. Between 2025 and 2027, multiple companies will bring platforms to market. Combined with new FDA approvals, the next five years will increase the indications and procedures performed. Lucintel has similar projections based on the aging population, shorter length of stay for hospitalizations and the focus on improved reimbursement.- Expansion of Transcatheter Valves: Edwards reported $5.4 billion in 2024 net sales with their TAVR products being their largest segment (February 2025). Edwards and others will continue to invest in next generation platforms for lower profile delivery systems to reduce valve-in-valve and valve-in-ring procedures. If they are successful, procedures for younger and lower risk patients will increase.
- Commercialization of The Tricuspid Valve: Abbott reported strong commercialization of Tri Clip during 2024 (January 2025). Expanding clinical data will support the commercialization of other tricuspid repair devices and will shift tricuspid repair from a niche procedure to a routine option for high-risk patients.
- Extension of Portfolio: Boston Scientific projected 2025 revenue growth of 10%-12% (February 2025), with their cardiovascular portfolio being a significant growth driver. Competitive pressure and the expansion of devices into specialty areas will fuel consolidation through partnerships and acquisitions.
- Reimbursement Driven Indication Expansion: The 2025 ACC/AHA guidelines maintained the use of heart teams for valve-related decisions (March 2025). New evidence will impact reimbursement and will affect which valve-related procedures are performed.
- Manufacturing and Training Capacity: Investments in Edwards’ first Asia-Pacific Innovation and Training Center in Singapore (2025) will increase local physician support. Similar investments will reduce barriers to adoption and increase operator proficiency and procedure volume in underpenetrated markets, especially in China and Southeast Asia.
Strategic Growth Opportunities in the Structural Heart Device Market
The structural heart device market is Expected To Grow as The Following Trends Drive Care Away from Open-heart Surgery: Improving imaging, transcatheter options, and the aging population. From 2024 to 2026, several clinical studies are expected to launch and build evidence, along with hospital capacity and payment reform, to expand treatment pathways. Lucintel has identified at least five additional opportunities beyond valve replacement.- Earlier Intervention Therapies: It is expected that treating individuals with moderate valve disease before they suffer irreversible damage to the heart will create an expanded opportunity. October 2024 saw the release of preliminary data from the EARLY TAVR trial including 901 participants. In the following years, there will be increased demand for lower-profile devices. In addition, increased diagnostic testing to identify previously undiagnosed cases will drive the need for a referral pathway for the procedure.
- Tricuspid and Mitral Therapies: Until recently, there has not been a financial incentive for device manufacturers to develop therapies for the tricuspid valve. Results from Abbott’s TRILUMINATE trial of the tricuspid valve device are expected in 2025. One of the first valves developed was for the mitral position. It is expected that further research and development in this area will drive the market for other procedures beyond the aortic position.
- Ambulatory Care Models: Continuous improvements to catheter-based technologies are expected to extend same day discharge procedures to higher-risk populations, further improving the efficiency of the healthcare system.
- New Markets: Brazil and India are expected to remain high growth areas for structural heart device procedures and therapies in the future, along with other regions in Southeast Asia and Latin America.
- Remote monitoring and imaging analytics can create a recurring revenue source post implant. The FDA's acceptance of 500+ AI-enabled medical devices in Feb. 2025 sets a clear pathway for clinically validated software. Companies integrating surveillance, alerts, and workflow tools can foster better relationships with hospitals. It will take 3-5 years for the relationships to deepen.
Structural Heart Device Market Drivers and Challenges
Drivers for the structural heart device market include development of technologies, reimbursement and regulatory policies, a growing aging population, increasing preference for less invasive procedures, and higher incidence of cardiovascular diseases. Leading devices include transcatheter valves, closure devices, and implantable pumps. Demand is also increasing for repair and replacement procedures for valves and other structures. Innovation, especially in the field of structural heart devices, is rapidly developing. Lucintel expects that by balancing risks, devices may prove their worth over the next 5 years.The factors responsible for driving this market include:
- Increasing Cardiovascular Diseases: The number of patients with aortic stenosis and mitral regurgitation as well as with other forms of heart failure and congenital heart defects is growing. In January 2025, the global population 65 years and older was above 800 million. It is anticipated that demand will continue to grow for interventions related to aging of the heart valves. Earlier and better diagnostics, as well as improved echocardiographic screenings, are resulting in identification and treatment of patients who were previously undiagnosed. It is expected that in the next 3-5 years the number of patients who will undergo a transcatheter aortic valve replacement as well as a transcatheter mitral valve repair will continue to increase.
- Preference for Minimally Invasive Procedures: The catheter-based procedures have an edge over the conventional procedures because they inflict less surgical trauma and help reduce the need for long stays in the ICU and in a hospital. In February 2025, a number of clinical programs had reported performing transcatheter procedures via small peripheral vascular access sites as an alternative to open-chest surgical procedures. The programs reported various interventions that enabled same-day or next-day discharge. The potential of the procedures to treat elderly and higher-risk patients who are not able to withstand conventional surgery is promising. In the next three to five years, as evidence continues to build, the procedures are expected to become even more common. Additionally, as hospital administrators prioritize operational efficiency, the minimally invasive procedures will also become more common.
- Improved Technology and Product Development: Continuous improvements in valve technology, along with imaging and other related fields, is making catheter-based devices more reliable and easier to use. In March 2025, a number of catheter-based systems were developed to improve visualization, control, and guidance during the procedure. The catheter platforms were designed for access vessels of 15 French and less. The development can potentially improve the success rate of catheter-based procedures and enable the treatment of a broader range of patients. The competitive environment and the need to develop next-generation products will drive improvement in catheter-based devices and their applications in the next three to five years.
- Broadening Clinical Indications: Devices are being approved for use on broader populations, including those outside of the traditional high-surgical-risk cohort. Examples of positive trial results for transcatheter therapies treating a wider patient population were announced in April 2025. They included lower-risk patients as well as indications for valve-in-valve procedures. With longer-term positive results, payers, hospitals and industry guidelines may also become more liberal, thereby expanding reimbursement and product approval. Wider clinical indications will occur in the next 3-5 years, but manufacturers should continue to demonstrate durability through comparative effectiveness research in order to expand the addressable patient market.
- Improving Healthcare Infrastructure: Improvements in cardiac imaging, interventional cardiology, hybrid operating rooms and catheterization laboratories have helped improve access to structural heart procedures. In May 2025, developing health systems established comprehensive heart teams and advanced imaging, while developed systems focused on expanding outpatient heart procedures. Reimbursement policies focused on clinical outcomes and reduced length of stay would further support adoption. Improvements in healthcare infrastructure, plus value-based payment policies would create a more favorable environment for expanding structural heart procedures to secondary and tertiary centers. However, persistent differences in levels of funding and expertise would continue to be a barrier for deeper market penetration.
The challenges facing this market include:
- High Costs of Devices and Procedures: The usage of structural heart systems requires a range of expensive devices and has associated high costs. In June 2025, many healthcare providers were still performing procedures that cost tens of thousands of dollars per patient, before considering follow-up care. There are concerns about affordability for hospitals and patients. There are budgetary constraints, especially in developing countries and public healthcare systems. There is pressure to analyze costs and scrutinize prices. In the next three to five years, manufacturers are expected to demonstrate total cost savings, for example through reduction in hospital stay, complications and repeat procedures.
- Clinical Uncertainty and Long Term Durability: There is uncertainty in the medium to long term regarding thrombus, infection, conduction block, and reintervention. There is particular uncertainty in dealing with younger patients. In July 2025, long term follows up studies of patients continued to study the durability of devices and compare effectiveness with other competing devices. There is increasing demand by regulators and physicians to have evidence beyond short term procedural success. There is uncertainty regarding long term outcomes of devices. In the next three to five years, there may be particular reliance on registries, randomized controlled trials, and post-market studies to determine outcomes of devices in lower risk populations.
- Barriers To Access: Such as regulatory and procedural barriers, restrict advancement of structural heart devices. Manufacturers must navigate challenging approval processes as well as varying expectations for device safety, clinical trial designs, and post-market surveillance requirements. Some processes require highly specialized personnel (heart teams, imaging specialists, anesthesiologists) that are not uniformly distributed. The next 3-5 years may bring challenges for the structural heart device industry as delays in regulatory approvals and workforce shortages slow the introduction of new devices and geographic expansion. Standardization of training and evidence may ease delays.
List of Structural Heart Device Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies structural heart device market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the structural heart device market companies profiled in this report include:
- St. Jude Medical, Inc.
- Boston Scientific Corporation
- Abbott Laboratories
- Edwards Lifesciences Corporation
- Medtronic Public Limited Company
- LivaNova PLC
- C. R. Bard, Inc.
- CryoLife Inc.
- JenaValve Technology Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
Structural Heart Device Market by Segment
The study includes a forecast for the global structural heart device market by procedure, position, and region.Procedure [Value ($M) from 2019 to 2035]:
- Repair
- Replacement
Position [Value ($M) from 2019 to 2035]:
- Aorta
- Mitral
- Others
Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Structural Heart Device Market
The market for structural heart devices is moving toward broader transcatheter approaches from valve replacements, primarily due to changes in regulatory and hospital environments. Based on our market analysis, the 2025-2027 time frame will mainly be influenced by new device launches, localized production, and strategic partnerships.- United States: Expansion of Abbott’s transcatheter valve platform and Edwards Lifesciences’s commercialization efforts gained momentum following the FDA’s broader indication for the company’s Navitor and Sapien 3 systems, respectively, in March 2025. Given the rising procedural options, we anticipate greater adoption at U.S. hospitals over the next three to five years.
- China: Venus Medtech continued its commercialization efforts for transcatheter aortic and mitral valve replacement (TAVR) devices and reported more than 30,000 cumulative implants for its first generation Skeeever TAVR device by December 2025. Additionally, the China’s central procurement system benefitted other domestic producers. We expect the localization of the procurement system to accelerate China’s shift from the use of imported to nationally manufactured devices.
- Germany: Siemens Healthineers and Edwards Lifesciences continue to work on image-guided structural-heart procedures, and the combination of advanced imaging and centralized service planning should standardize procedures more. Germany’s federal hospital reform took effect in January 2025. Standards should help increase the efficiency of integrated service planning and refine cardiovascular procedures.
- India: Meril Life Sciences expanded its production of MyVal transcatheter heart valves and surpassed 20,000 implants by September 2025. MyVal is a relatively lower-cost transcatheter heart valve, and along with the increase in domestic production, Meril should be well-positioned for export. Alongside Meril, other Indian manufacturers will likely focus on structural heart valve implants, according to the increase in local capacities, and costs.
- Japan: The Ministry of Health, Labour and Welfare approved reimbursement for select transcatheter valve procedures in April 2025. Terumo, too, continued its investment in cardiovascular devices. More reimbursement and better local clinical infrastructure will likely accelerate structural-heart procedures going beyond major academic centers in Japan.
Features of the Global Structural Heart Device Market
- Market Size Estimates: structural heart device market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: structural heart device market size by procedure, position, and region in terms of value ($M).
- Regional Analysis: structural heart device market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different procedure, position, and regions for the structural heart device market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the structural heart device market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the structural heart device market by procedure (repair and replacement), position (aorta, mitral, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- St. Jude Medical, Inc.
- Boston Scientific Corporation
- Abbott Laboratories
- Edwards Lifesciences Corporation
- Medtronic Public Limited Company
- LivaNova PLC
- C. R. Bard, Inc.
- CryoLife Inc.
- JenaValve Technology Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

